Patients can explore the latest weight loss medications, understand their coverage and get comprehensive, high-quality care all in one platform

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, announced today it has expanded its Body Program offering with the launch of Zepbound (tirzepatide) injection, the latest FDA-approved weight loss treatment from Eli Lilly and Company. Now, patients can come to Ro to access a broader range of weight loss treatment options based on their goals, insurance, budget, and a licensed provider's assessment. Each patient's Body Program journey is supported by personalized provider care, diagnostic testing, nurse coaching, and education.

In a 72-week clinical trial, Zepbound helped people without diabetes lose an average of 48 pounds, or about 20% of their body weight, when they paired the highest maintenance dose with diet and exercise changes (vs 3% with diet and exercise alone). Patients can work with their provider to determine if treatment is appropriate after completing an Online Visit and lab testing via Quest Diagnostics or Ro's at-home collection kit.

"The possibilities of a world with Zepbound cannot be understated. Hopefully, with more options and more competition, we'll see expanded coverage of these innovative treatments and increased access for patients." said Zachariah Reitano, co-founder and CEO of Ro.

Launched in January 2023, Ro's Body Program has since grown to be the most comprehensive, high-quality weight loss offering available via telehealth, with additional medications and new tools to help patients reach their goals. This expansion includes:

Expanded GLP-1/GIP formulary to medication options that include Wegovy, Ozempic, Saxenda and now, Zepbound.

Integrated benefits verification to help patients understand their insurance coverage at the beginning and throughout their journey;

Automated side effect tracking to help patients communicate with their care team when additional support is needed. This data empowers Ro-affiliated providers to best support patients as they titrate medications;

Integrated AI learning models to perform clerical tasks and give providers additional leverage to spend more time with patients and less on manual, administrative tasks;

Integrated with Apple Health to enable patients to share their weight loss data with their provider automatically; and more.

"Zepbound is poised to be the most impactful anti-obesity medication we've seen so far in our lifetime. In the Body Program, we're pairing access to Zepbound and other effective medication options conveniently alongside everything a patient needs to start their treatment and at each step in their care journey," said Dr. Melynda Barnes, Chief Medical Officer of Ro. "Through Ro, patients can connect with a provider to evaluate all their options for GLP-1 treatment, understand their insurance coverage, and access ongoing, personalized provider care and coaching."

To learn more about the Ro Body Program, click here. To see more safety information for Zepbound, including a Boxed Warning, click here or see below.